• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Innospec Inc.

    5/14/25 6:04:58 AM ET
    $IOSP
    Major Chemicals
    Industrials
    Get the next $IOSP alert in real time by email
    8-K
    false 0001054905 0001054905 2025-05-09 2025-05-09
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 9, 2025

     

     

    INNOSPEC INC.

    (Exact name of registrant as specified in its charter)

     

     

    Commission File Number: 1-13879

     

    Delaware   98-0181725

    (State or other jurisdiction

    of incorporation)

     

    (IRS Employer

    Identification No.)

    8310 South Valley Highway, Suite 350

    Englewood, Colorado, 80112

    (Address of principal executive offices, including zip code)

    (303)792-5554

    (Registrant’s telephone number, including area code)

     

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of exchange

    on which registered

    Common Stock   IOSP   NASDAQ

     

     
     


    Item 5.07.

    Submission of Matters to a Vote of Security Holders

    Proposal 1 – Election of three Class III directors

    At the annual meeting of Innospec shareholders held on May 9, 2025, the shareholders elected the directors nominated in the Innospec Proxy Statement, dated March 26, with the following votes for and votes withheld:

     

    Director

       Votes For      Votes Withheld      Broker Non-Votes  

    David F. Landless

         21,710,227        1,062,931        958,863  

    Lawrence J. Padfield

         22,069,282        703,876        958,863  

    Patrick S. Williams

         22,438,029        335,129        958,863  

    Proposal 2 – Advisory approval of the Company’s executive compensation

     

    For:

         21,973,642  

    Withheld:

         778,543  

    Abstain:

         20,972  

    Broker Non-Votes:

         958,863  

    Proposal 3—Ratification of the appointment of the Company’s independent registered public accounting firm for 2025

     

    For:

         23,685,327  

    Withheld:

         16,248  

    Abstain:

         30,446  


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          INNOSPEC INC.
    Date: May 14, 2025     By:  

    /s/ David B. Jones

          David B. Jones
          Senior Vice President, General Counsel and Chief Compliance Officer
    Get the next $IOSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOSP

    DatePrice TargetRatingAnalyst
    4/21/2025$115.00Neutral → Buy
    Seaport Research Partners
    3/30/2022Neutral
    Seaport Research Partners
    More analyst ratings